MA47743A - Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations - Google Patents

Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations

Info

Publication number
MA47743A
MA47743A MA047743A MA47743A MA47743A MA 47743 A MA47743 A MA 47743A MA 047743 A MA047743 A MA 047743A MA 47743 A MA47743 A MA 47743A MA 47743 A MA47743 A MA 47743A
Authority
MA
Morocco
Prior art keywords
beta
solid forms
compositions including
lactamase inhibitor
combination compositions
Prior art date
Application number
MA047743A
Other languages
English (en)
Inventor
Jean-Baptiste Arlin
Gerald Brenner
Christopher J Burns
Casares Ana Fernandez
Timothy Henkel
Daniel Mcgarry
Daniel C Pevear
Lawrence Rosen
Luigi Xerri
Original Assignee
Venatorx Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Venatorx Pharmaceuticals Inc filed Critical Venatorx Pharmaceuticals Inc
Publication of MA47743A publication Critical patent/MA47743A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA047743A 2017-03-06 2018-03-05 Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations MA47743A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762467750P 2017-03-06 2017-03-06
US201762467752P 2017-03-06 2017-03-06
US201762564989P 2017-09-28 2017-09-28
US201762564990P 2017-09-28 2017-09-28

Publications (1)

Publication Number Publication Date
MA47743A true MA47743A (fr) 2020-01-15

Family

ID=63448038

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047743A MA47743A (fr) 2017-03-06 2018-03-05 Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations

Country Status (16)

Country Link
US (4) US11091505B2 (fr)
EP (1) EP3592362B1 (fr)
JP (2) JP7634934B2 (fr)
KR (1) KR102603489B1 (fr)
CN (2) CN110678186A (fr)
AU (1) AU2018230991B2 (fr)
CA (1) CA3055253A1 (fr)
ES (1) ES3015371T3 (fr)
HR (1) HRP20250459T1 (fr)
IL (2) IL301591B1 (fr)
MA (1) MA47743A (fr)
MY (1) MY196966A (fr)
PH (1) PH12019502037B1 (fr)
PL (1) PL3592362T3 (fr)
SG (1) SG11201908181XA (fr)
WO (1) WO2018165048A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (fr) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
WO2017100537A1 (fr) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamases
WO2018027062A1 (fr) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Composés contenant du bore
ES3015371T3 (en) 2017-03-06 2025-05-05 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2018218190A1 (fr) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de protéines de liaison à la pénicilline
EP3630783A4 (fr) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. Inhibiteurs protéiques de liaison à la pénicilline
WO2019226931A1 (fr) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
US20220054513A1 (en) * 2018-09-12 2022-02-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
WO2020112542A1 (fr) 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021454A (en) 1911-01-23 1912-03-26 Thomas Ernest Davis Serving-table.
US7271186B1 (en) 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
IN2012DN03023A (fr) 2004-01-26 2015-07-31 Merck Sharp & Dohme
NZ598172A (en) 2004-03-30 2013-08-30 Millennium Pharm Inc Synthesis of boronic ester and acid compounds
CN1965838A (zh) * 2005-11-17 2007-05-23 李海超 含头孢匹胺和β-内酰胺酶抑制剂的药物组合物
CN101129382B (zh) 2006-08-25 2013-12-25 天津和美生物技术有限公司 含β-内酰胺类抗生素和缓冲组分的抗生素复方
US20100120715A1 (en) 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
TW200936143A (en) 2007-11-13 2009-09-01 Protez Pharmaceuticals Inc Beta-lactamase inhibitors
CN101918407B (zh) 2008-01-18 2014-02-26 默沙东公司 β-内酰胺酶抑制剂
US20100292185A1 (en) 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
KR102205755B1 (ko) 2010-08-10 2021-01-22 렘펙스 파머수티클스 인코퍼레이티드 고리형 보론산 에스터 유도체의 결정 형태
RU2569059C2 (ru) 2011-07-26 2015-11-20 Вокхардт Лимитед Фармацевтические композиции, содержащие бета-лактамный антибиотик, сульбактам и ингибитор бета-лактамаз
WO2013053372A1 (fr) 2011-10-13 2013-04-18 Therabor Pharmaceuticals Inhibiteurs de type acide boronique de bêta-lactamases
KR101288157B1 (ko) 2011-12-07 2013-07-19 백병하 기존 세파계 항생제 및 베타 락타마제 저해제로 배합된 내성균주에 기인한 감염증의 치료 및 예방을 위한 복합항생제
JP5798495B2 (ja) 2012-01-13 2015-10-21 住友理工株式会社 配線体接続構造体
US20150119363A1 (en) 2012-02-15 2015-04-30 Rempex Pharmaceuticals, Inc.. Methods of treating bacterial infections
DE102012101680A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
PT2928898T (pt) 2012-12-07 2021-07-05 Venatorx Pharmaceuticals Inc Inibidores de beta-lactamase
JP2016509594A (ja) 2013-01-04 2016-03-31 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP6324409B2 (ja) 2013-01-04 2018-05-16 レンペックス・ファーマシューティカルズ・インコーポレイテッド ボロン酸誘導体及びその治療的使用
JP6346904B2 (ja) 2013-01-10 2018-06-20 ベナトルクス ファーマシューティカルズ,インク. ベータ−ラクタマーゼ阻害剤
WO2014151958A1 (fr) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de bêta-lactamase
US9120796B2 (en) * 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
WO2015157618A1 (fr) * 2014-04-11 2015-10-15 The Texas A&M University System Nouveaux inhibiteurs de la new delhi métallo-bêta-lactamase (ndm-1)
US20150361107A1 (en) 2014-06-11 2015-12-17 VenatoRx Pharmaceuticals, Inc. Orally bioavailable beta-lactamase inhibitors
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
KR101935186B1 (ko) 2014-09-04 2019-01-03 시오노기세야쿠 가부시키가이샤 카테콜기를 갖는 세팔로스포린류를 함유하는 제제
CN107207537B (zh) 2014-12-19 2019-05-31 莱姆派克斯制药公司 用于生产硼酸衍生物的设备和连续流方法
CN108472284A (zh) 2015-09-11 2018-08-31 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
CN105801610B (zh) 2016-04-19 2018-05-18 武汉维舜医药科技有限公司 新型广谱β-内酰胺酶抑制剂
UA124464C2 (uk) 2016-06-30 2021-09-22 Кьюпекс Біофарма, Інк. Похідні боронової кислоти та їх терапевтичні застосування
WO2018027062A1 (fr) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Composés contenant du bore
ES3015371T3 (en) 2017-03-06 2025-05-05 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
WO2019226931A1 (fr) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Inhibiteurs de protéine de liaison à la pénicilline
US20220054513A1 (en) 2018-09-12 2022-02-24 VenatoRx Pharmaceuticals, Inc. Combination compositions comprising a beta-lactamase inhibitor
WO2020112542A1 (fr) 2018-11-29 2020-06-04 VenatoRx Pharmaceuticals, Inc. Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations

Also Published As

Publication number Publication date
BR112019018447A2 (pt) 2020-04-14
IL268981B2 (en) 2023-09-01
US20220002322A1 (en) 2022-01-06
ES3015371T3 (en) 2025-05-05
IL268981A (en) 2019-10-31
US20250320235A1 (en) 2025-10-16
CN117398398A (zh) 2024-01-16
SG11201908181XA (en) 2019-10-30
AU2018230991A1 (en) 2019-09-19
JP2020510661A (ja) 2020-04-09
IL301591B1 (en) 2025-11-01
CA3055253A1 (fr) 2018-09-13
US11091505B2 (en) 2021-08-17
EP3592362A1 (fr) 2020-01-15
EP3592362C0 (fr) 2025-02-19
KR20190117790A (ko) 2019-10-16
AU2018230991B2 (en) 2023-07-13
IL301591A (en) 2023-05-01
US11820784B2 (en) 2023-11-21
US12187752B2 (en) 2025-01-07
EP3592362A4 (fr) 2020-09-02
PH12019502037B1 (en) 2024-06-05
HRP20250459T1 (hr) 2025-06-06
US20200010485A1 (en) 2020-01-09
KR102603489B1 (ko) 2023-11-16
EP3592362B1 (fr) 2025-02-19
JP7634934B2 (ja) 2025-02-25
PH12019502037A1 (en) 2020-03-09
JP2023061946A (ja) 2023-05-02
WO2018165048A1 (fr) 2018-09-13
IL268981B1 (en) 2023-05-01
CN110678186A (zh) 2020-01-10
US20240101580A1 (en) 2024-03-28
MY196966A (en) 2023-05-15
PL3592362T3 (pl) 2025-06-23

Similar Documents

Publication Publication Date Title
MA47743A (fr) Formes solides et compositions de combinaison comprenant un inhibiteur de bêta-lactamase et leurs utilisations
EP3886798A4 (fr) Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
EP3870579A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3600273A4 (fr) Inhibiteurs de cd73 et leurs utilisations
EP3801065A4 (fr) Compositions bactériennes spécifiques et leurs utilisations
EP3813877A4 (fr) Compositions anti-cd24 et leurs utilisations
EP3866789A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
MA51288A (fr) Analogues d'incrétine et leurs utilisations
EP3790861A4 (fr) Compositions sénolytiques et utilisations associées
EP3419676A4 (fr) Compositions antimicrobiennes et leurs utilisations
MA53243A (fr) Compositions comprenant une combinaison de ipilimumab et nivolumab
EP3746075A4 (fr) Inhibiteurs de gcn2 et leurs utilisations
EP4076448A4 (fr) Oxadiazoles fluoroalkylés et leurs utilisations
MA52483A (fr) Dérivés de gip et leurs utilisations
EP3886843A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3749314A4 (fr) Méthotrexate alpha-polyglutamaté et utilisations associées
MA51287A (fr) Analogues d'incrétine et leurs utilisations
EP3787607C0 (fr) Compositions de caroténoïdes et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3413816A4 (fr) Compositions hydratantes et utilisations associées
EP3328199A4 (fr) Compositions antimicrobiennes et leurs utilisations
EP3624797A4 (fr) Inhibiteurs de kinase et leurs utilisations
EP3860636A4 (fr) Inhibiteurs de matriptase 2 et leurs utilisations
MA45943A (fr) Compositions ignifuges et leurs utilisations
EP3720434A4 (fr) Mélanges non racémiques et leurs utilisations